Search research articles
Contact Us
Filters
Showing results (171-180 of 179) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 179 results.
Lancet (London, England)
|
February 15, 2026
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study
M Lia Palomba, Stephen J Schuster, Reem Karmali, et al.
The New England Journal of Medicine
|
June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Jason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, et al.
The New England Journal of Medicine
|
December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Frederick L Locke, David B Miklos, Caron A Jacobson, et al.
Science Translational Medicine
|
August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells
Brian J Cameron, Andrew B Gerry, Joseph Dukes, et al.
Bone Marrow Transplantation
|
March 2, 2025
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
Mohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 18, 2023
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
David J Chung, Nina Shah, Juan Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2024
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
David J Chung, Nina Shah, Juan Wu, et al.
Nature Medicine
|
July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 179) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 179 results.
Lancet (London, England)
|
February 15, 2026
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study
M Lia Palomba, Stephen J Schuster, Reem Karmali, et al.
The New England Journal of Medicine
|
June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Jason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, et al.
The New England Journal of Medicine
|
December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Frederick L Locke, David B Miklos, Caron A Jacobson, et al.
Science Translational Medicine
|
August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells
Brian J Cameron, Andrew B Gerry, Joseph Dukes, et al.
Bone Marrow Transplantation
|
March 2, 2025
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
Mohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 18, 2023
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
David J Chung, Nina Shah, Juan Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2024
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
David J Chung, Nina Shah, Juan Wu, et al.
Nature Medicine
|
July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Page
of 18